Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROMES: PROspective, Non-Interventional, Observational, Longitudinal Study to Describe the Safety Profile of MESIGYNA® (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) as a Contraceptive Method for Women in Reproductive Age at the Outpatient Clinic

NCT03901131 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03901131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03901131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROMES: PROspective, Non-Interventional, Observational, Longitudinal Study to Describe the Safety Profile of MESIGYNA® (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) as a Contraceptive Method for Women in Reproductive Age at the Outpatient Clinic
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
August 26, 2019
Completion date
February 17, 2022
Enrollment
296 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

contraceptive